137 related articles for article (PubMed ID: 30210333)
1. Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists.
Wang L; Song T; Wang X; Li J
Front Pharmacol; 2018; 9():864. PubMed ID: 30210333
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
4. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
5. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
6. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
7. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
[TBL] [Abstract][Full Text] [Related]
8. Virtual Screening and Bioactivity Evaluation of Novel Androgen Receptor Antagonists From Anti-PCa Traditional Chinese Medicine Prescriptions.
Han W; Shi Y; Su J; Zhao Z; Wang X; Li J; Liu H
Front Chem; 2020; 8():582861. PubMed ID: 33094102
[TBL] [Abstract][Full Text] [Related]
9. Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site.
Liu Y; Wu M; Wang T; Xie Y; Cui X; He L; He Y; Li X; Liu M; Hu L; Cen S; Zhou J
Front Pharmacol; 2018; 9():1419. PubMed ID: 30555332
[TBL] [Abstract][Full Text] [Related]
10. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
11. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
14. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
16. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.
Attar RM; Jure-Kunkel M; Balog A; Cvijic ME; Dell-John J; Rizzo CA; Schweizer L; Spires TE; Platero JS; Obermeier M; Shan W; Salvati ME; Foster WR; Dinchuk J; Chen SJ; Vite G; Kramer R; Gottardis MM
Cancer Res; 2009 Aug; 69(16):6522-30. PubMed ID: 19654297
[TBL] [Abstract][Full Text] [Related]
17. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
[TBL] [Abstract][Full Text] [Related]
18. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response.
Siciliano T; Simons IH; Beier AK; Ebersbach C; Aksoy C; Seed RI; Stope MB; Thomas C; Erb HHH
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575023
[TBL] [Abstract][Full Text] [Related]
20. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.
Tian X; He Y; Zhou J
Front Pharmacol; 2015; 6():57. PubMed ID: 25852559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
